A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

Description

The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for Pancreatic Cancer.

Conditions

Pancreatic Neoplasms

Talk to us

Study Overview

On this page

Study Details

Study overview

The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for Pancreatic Cancer.

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

Condition
Pancreatic Neoplasms
Intervention / Treatment

-

Contacts and Locations

Norwalk

Nuvance Health, Norwalk, Connecticut, United States, 06856

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Prior history of pancreatic cancer.
  • 2. Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.
  • 3. Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).
  • 4. Hereditary pancreatitis.
  • 5. eGFR \< 30 mL/min
  • 6. Contraindication to MRI examination or gadolinium contrast.
  • 7. Pregnant or nursing women.
  • 8. Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.

Ages Eligible for Study

50 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Nuvance Health,

Richard Frank, MD, PRINCIPAL_INVESTIGATOR, Nuvance Health

Study Record Dates

2026-11